Pharming Group N.V. Q3 2025 Earnings Recap

Pharming Group N.V. achieved robust growth in Q3 2025, with total revenues increasing by 30% year-over-year to $82 million, driven by strong performance in its commercial products RUCONEST and Joenja.

Key Takeaways

• Operating profit surged nearly fourfold to $15.8 million, with operating cash flow reaching $32 million.
• RUCONEST revenue grew 29%, benefiting from increased prescriber adoption and new patient enrollments.
• Joenja saw a 35% revenue increase, supported by a 25% rise in U.S. patients on therapy and an expanding patient funnel.
• The company raised its full-year 2025 revenue guidance to a range of $360 million to $375 million, reflecting ongoing commercial momentum.
• Planned reductions in G&A headcount will optimize capital for high-growth initiatives, enhancing Pharming's competitive positioning in the rare disease market.